Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease

Clinical trial NCT07681297 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07681297
Sponsor: National University Hospital, Singapore
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor Cancer Triple-Negative Breast Cancer (TNBC)CNS Disease Breast Cancer

Start date: 2026-08-01
Primary completion: 2028-08-01
Enrollment: 154

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.